Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Februar 2026 16:05 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT WORLDSYMPOSIUM 2026
03. Februar 2026 09:10 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
18. Dezember 2025 08:05 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo announces it has begun a rolling submission of its BLA to the FDA for , an investigational gene therapy for adults with Fabry disease
02. Dezember 2025 08:05 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Sangamo Therapeutics today announced that the FDA has granted Fast Track Designation to ST-503 in chronic neuropathic pain
21. November 2025 08:05 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

U.S. FDA has accepted Sangamo’s request for a rolling submission and review of the BLA for ST-920 in Fabry disease
06. November 2025 08:01 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2025 FINANCIAL RESULTS
30. Oktober 2025 16:01 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 EARNINGS CALL
04. September 2025 08:05 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM 2025
07. August 2025 16:01 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo Therapeutics reports recent business highlights and second quarter 2025 financial results
31. Juli 2025 16:05 ET | Quelle: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second...

Nächste Seite